This page shows the latest Apeiron news and features for those working in and with pharma, biotech and healthcare.
Apeiron Biologics also got the go-ahead for Dinutuximab beta as a treatment for high-risk neuroblastoma, an orphan indication.
BioNtech - signed last year alongside smaller deals with Selecta, Evotec and Apeiron Biologics.
Set to develop five cancer therapies
Meanwhile, the two companies have also agreed to work together with Apeiron Biologics on novel, small-molecule immuno-oncology therapies. ... Sanofi will support two years of research funding for Evotec and Apeiron and could potentially yield more than
SPA/P2 (as combination). 350. Apeiron Biologics AG/GSK. APN01 - recombinant human angiotensin converting enzyme 2 (rhACE2) in ARDS.
GSK enters licensing deal for ARDS enzyme. Apeiron has granted GSK exclusive rights to its APN01 enzyme, in phase I development to treat Acute Respiratory Distress Syndrome. ... The deal will see GSK pay Apeiron an up-front payment of £11m cash and
More from news
Approximately 2 fully matching, plus 4 partially matching documents found.
Immunology deals. In addition to this and in keeping with the industry fashion, Sanofi has ventured into immuno-oncology with Evotec / Apeiron Biologics. ... As a strategic collaboration it is fairly risk sparing and accesses Apeiron's immunological
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Apeiron bolsters management board. Peter Llewellyn-Davies joins as its CFO and CBO. ... Viennese cancer-immunotherapy focused group Apeiron Biologics has appointed a new chief financial officer and chief business officer in the form of Peter
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...